Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Charles Lynde

Showing results (111-120 of 141) with videos related to

Pageof 15
Sort By:
Journal of the American Academy of Dermatology|July 25, 2024
Efficacy and safety of deuruxolitinib, an oral selective Janus kinase inhibitor, in adults with alopecia areata: Results from the Phase 3 randomized, controlled trial (THRIVE-AA1)Brett King, Maryanne M Senna, Natasha A Mesinkovska, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|June 29, 2022
Comparative effectiveness of biologics in clinical practice: week 12 primary outcomes from an international observational psoriasis study of health outcomes (PSoHO)Andreas Pinter, Luis Puig, Knut Schäkel, et al.
Annals of the Rheumatic Diseases|January 7, 2015
The effects of tumour necrosis factor inhibitors, methotrexate, non-steroidal anti-inflammatory drugs and corticosteroids on cardiovascular events in rheumatoid arthritis, psoriasis and psoriatic arthritis: a systematic review and meta-analysisCamille Roubille, Vincent Richer, Tara Starnino, et al.
Journal of the American Academy of Dermatology|September 20, 2020
Twice-weekly topical calcipotriene/betamethasone dipropionate foam as proactive management of plaque psoriasis increases time in remission and is well tolerated over 52 weeks (PSO-LONG trial)Mark Lebwohl, Leon Kircik, Jean-Philippe Lacour, et al.
The Journal of Allergy and Clinical Immunology|August 17, 2021
Upadacitinib plus topical corticosteroids in atopic dermatitis: Week 52 AD Up study resultsJonathan I Silverberg, Marjolein de Bruin-Weller, Thomas Bieber, et al.
Lancet (London, England)|April 19, 2025
Efficacy and safety of topical delgocitinib cream versus oral alitretinoin capsules in adults with severe chronic hand eczema (DELTA FORCE): a 24-week, randomised, head-to-head, phase 3 trialAna Maria Giménez-Arnau, Andreas Pinter, Wiebke Sondermann, et al.
The Journal of Rheumatology|May 3, 2016
Dr. Roubille, et al replyCamille Roubille, Vincent Richer, Tara Starnino, et al.
Arthritis Care & Research|November 25, 2014
Meta-analysis of tumor necrosis factor inhibitors and glucocorticoids on bone density in rheumatoid arthritis and ankylosing spondylitis trialsStephanie Siu, Boulos Haraoui, Robert Bissonnette, et al.
Journal of Cutaneous Medicine and Surgery|November 9, 2016
Definition of Moderate to Severe Hidradenitis Suppurativa: A Position Paper by the Canadian Hidradenitis Suppurativa Foundation (CHSF)Afsaneh Alavi, David N Adam, Ra'ed Alhusayen, et al.
JAMA Dermatology|August 21, 2024
Tyrosine Kinase 2 Inhibition With Zasocitinib (TAK-279) in Psoriasis: A Randomized Clinical TrialApril W Armstrong, Melinda Gooderham, Charles Lynde, et al.
Pageof 15

Showing results (111-120 of 141) with videos related to

Sort By:
Pageof 15
Journal of the American Academy of Dermatology|July 25, 2024
Efficacy and safety of deuruxolitinib, an oral selective Janus kinase inhibitor, in adults with alopecia areata: Results from the Phase 3 randomized, controlled trial (THRIVE-AA1)Brett King, Maryanne M Senna, Natasha A Mesinkovska, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|June 29, 2022
Comparative effectiveness of biologics in clinical practice: week 12 primary outcomes from an international observational psoriasis study of health outcomes (PSoHO)Andreas Pinter, Luis Puig, Knut Schäkel, et al.
Annals of the Rheumatic Diseases|January 7, 2015
The effects of tumour necrosis factor inhibitors, methotrexate, non-steroidal anti-inflammatory drugs and corticosteroids on cardiovascular events in rheumatoid arthritis, psoriasis and psoriatic arthritis: a systematic review and meta-analysisCamille Roubille, Vincent Richer, Tara Starnino, et al.
Journal of the American Academy of Dermatology|September 20, 2020
Twice-weekly topical calcipotriene/betamethasone dipropionate foam as proactive management of plaque psoriasis increases time in remission and is well tolerated over 52 weeks (PSO-LONG trial)Mark Lebwohl, Leon Kircik, Jean-Philippe Lacour, et al.
The Journal of Allergy and Clinical Immunology|August 17, 2021
Upadacitinib plus topical corticosteroids in atopic dermatitis: Week 52 AD Up study resultsJonathan I Silverberg, Marjolein de Bruin-Weller, Thomas Bieber, et al.
Lancet (London, England)|April 19, 2025
Efficacy and safety of topical delgocitinib cream versus oral alitretinoin capsules in adults with severe chronic hand eczema (DELTA FORCE): a 24-week, randomised, head-to-head, phase 3 trialAna Maria Giménez-Arnau, Andreas Pinter, Wiebke Sondermann, et al.
The Journal of Rheumatology|May 3, 2016
Dr. Roubille, et al replyCamille Roubille, Vincent Richer, Tara Starnino, et al.
Arthritis Care & Research|November 25, 2014
Meta-analysis of tumor necrosis factor inhibitors and glucocorticoids on bone density in rheumatoid arthritis and ankylosing spondylitis trialsStephanie Siu, Boulos Haraoui, Robert Bissonnette, et al.
Journal of Cutaneous Medicine and Surgery|November 9, 2016
Definition of Moderate to Severe Hidradenitis Suppurativa: A Position Paper by the Canadian Hidradenitis Suppurativa Foundation (CHSF)Afsaneh Alavi, David N Adam, Ra'ed Alhusayen, et al.
JAMA Dermatology|August 21, 2024
Tyrosine Kinase 2 Inhibition With Zasocitinib (TAK-279) in Psoriasis: A Randomized Clinical TrialApril W Armstrong, Melinda Gooderham, Charles Lynde, et al.
Pageof 15